PLRX Overview
Upcoming Projects (PLRX)
-
Don’t see a project related to the company you care about? Create your own!
Executed Projects (PLRX)
-
A Second Look: Discussing the recent data from the Phase 2a INTEGRIS-PSC Clinical Trial of Pliant's Bexotegrast in Patients with Primary Sclerosing Cholangitis
Ticker: PLRX
Executed On: Oct 11, 2023 at 01:30 PM EDT -
Discussing the recent data from the Phase 2a INTEGRIS-PSC Clinical Trial of Pliant's Bexotegrast in Patients with Primary Sclerosing Cholangitis
Ticker: PLRX
Executed On: Sep 29, 2023 at 03:00 PM EDT -
A Second Look: Examining the IPF treatment landscape with a focus on Pliant's bexotegrast, Fibrogen's pamrevlumab, and United Therapeutics' TYVASO (treprostinil)
Tickers: FGEN, PLRX, UTHR
Executed On: Jun 09, 2023 at 03:10 PM EDT -
Examining the IPF treatment landscape with a focus on Pliant's bexotegrast, Fibrogen's pamrevlumab, and United Therapeutics' TYVASO (treprostinil)
Tickers: FGEN, PLRX, UTHR
Executed On: Jun 01, 2023 at 07:00 AM EDT -
Following up on Pliant's PLN-74809 after the Phase 2a readout in IPF
Ticker: PLRX
Executed On: Jul 22, 2022 at 04:00 PM EDT -
A Second look into the IPF treatment landscape and emerging developmental therapeutics such as PLN-74809
Ticker: PLRX
Executed On: May 25, 2022 at 03:00 PM EDT -
A look into the IPF treatment landscape and emerging developmental therapeutics such as PLN-74809
Ticker: PLRX
Executed On: May 19, 2022 at 11:00 AM EDT
Expired Projects (PLRX)
-
Discussing Pliant Therapeutics’ PLN-74809 (Dual selective inhibitor of aVβ6/aVβ1) for treating Idiopathic pulmonary fibrosis
Ticker: PLRX
Execute By: Feb 28, 2023
Upcoming & Overdue Catalysts (PLRX)
-
Don’t see a catalyst related to the company you care about? Create your own!
Occurred Catalysts (PLRX)
-
Phase 2a PET interim data of Pliant Therapeutics' (PLRX) PLN-74809 Idiopathic pulmonary fibrosis to be released September 7, 2021
Ticker: PLRX
Occurred on: Sep 07, 2021
Strategic Initiatives (PLRX)
-
Don’t see a strategic initiative related to the company you care about? Create your own!
